The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease
An analytical article discusses the design and results of the recent COMPASS study. Particular attention is paid to the details of comparison of the efficacy and safety of rivaroxaban combined with acetylsalicylic acid and the efficacy and safety of drugs containing acetylsalicylic acid only in pati...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-10-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3735 |
| _version_ | 1797841988960124928 |
|---|---|
| author | O. V. Averkov |
| author_facet | O. V. Averkov |
| author_sort | O. V. Averkov |
| collection | DOAJ |
| description | An analytical article discusses the design and results of the recent COMPASS study. Particular attention is paid to the details of comparison of the efficacy and safety of rivaroxaban combined with acetylsalicylic acid and the efficacy and safety of drugs containing acetylsalicylic acid only in patients with stable coronary artery disease. In addition to a significant reduction in the risk of the sum of traditionally recognizable events (myocardial infarction, stroke, cardiovascular mortality), among the arguments in favour of fairly widespread prolonged use of the antiplatelet agent combined with anticoagulant is an attractive effect of the debated antithrombotic strategy on the overall mortality of patients, an acceptable ratio of efficacy and hemorrhagic safety, first of all the absence of the increased risk of fatal bleeding and the risk of intracranial bleeding. The article describes approaches to the selection of patients with coronary artery disease for the participation in the long-term treatment with rivaroxaban combined with acetylsalicylic acid. Alternative possibilities for enhancement of the secondary prophylactic effects of acetylsalicylic acid are mentioned, the arguments supporting the preference of the approach discussed in the article are presented. |
| first_indexed | 2024-04-09T16:40:28Z |
| format | Article |
| id | doaj.art-b167a0e48bdb49a8be19984ed9a5289d |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:40:28Z |
| publishDate | 2019-10-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b167a0e48bdb49a8be19984ed9a5289d2023-04-23T06:56:43ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-10-01016344110.21518/2079-701X-2019-16-34-413317The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery DiseaseO. V. Averkov0Municipal Clinical Hospital No. 15 named after О.М. Filatov; Pirogov Russian National Research Medical UniversityAn analytical article discusses the design and results of the recent COMPASS study. Particular attention is paid to the details of comparison of the efficacy and safety of rivaroxaban combined with acetylsalicylic acid and the efficacy and safety of drugs containing acetylsalicylic acid only in patients with stable coronary artery disease. In addition to a significant reduction in the risk of the sum of traditionally recognizable events (myocardial infarction, stroke, cardiovascular mortality), among the arguments in favour of fairly widespread prolonged use of the antiplatelet agent combined with anticoagulant is an attractive effect of the debated antithrombotic strategy on the overall mortality of patients, an acceptable ratio of efficacy and hemorrhagic safety, first of all the absence of the increased risk of fatal bleeding and the risk of intracranial bleeding. The article describes approaches to the selection of patients with coronary artery disease for the participation in the long-term treatment with rivaroxaban combined with acetylsalicylic acid. Alternative possibilities for enhancement of the secondary prophylactic effects of acetylsalicylic acid are mentioned, the arguments supporting the preference of the approach discussed in the article are presented.https://www.med-sovet.pro/jour/article/view/3735stable coronary artery diseaseprevious myocardial infarctionacetylsalicylic acidrivaroxabansecondary prevention |
| spellingShingle | O. V. Averkov The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease Медицинский совет stable coronary artery disease previous myocardial infarction acetylsalicylic acid rivaroxaban secondary prevention |
| title | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease |
| title_full | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease |
| title_fullStr | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease |
| title_full_unstemmed | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease |
| title_short | The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease |
| title_sort | role of rivaroxaban in the treatment of patients with stable coronary artery disease |
| topic | stable coronary artery disease previous myocardial infarction acetylsalicylic acid rivaroxaban secondary prevention |
| url | https://www.med-sovet.pro/jour/article/view/3735 |
| work_keys_str_mv | AT ovaverkov theroleofrivaroxabaninthetreatmentofpatientswithstablecoronaryarterydisease AT ovaverkov roleofrivaroxabaninthetreatmentofpatientswithstablecoronaryarterydisease |